How to buy Legend Biotech Corporation stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Legend Biotech Corporation stock

Own Legend Biotech Corporation stock in just a few minutes.

Legend Biotech Corporation is a biotechnology business based in the US. Legend Biotech Corporation shares (LEGN) are listed on the NASDAQ and all prices are listed in US Dollars. Legend Biotech Corporation employs 882 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Legend Biotech Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LEGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Legend Biotech Corporation share price

Use our graph to track the performance of LEGN stocks over time.

Legend Biotech Corporation shares at a glance

Information last updated 2021-04-20.
52-week range$23.41 - $43.24
50-day moving average $26.98
200-day moving average $28.02
Wall St. target price$49.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.32

Buy Legend Biotech Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Legend Biotech Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Legend Biotech Corporation financials

Revenue TTM $78.7 million
Gross profit TTM $78.7 million
Return on assets TTM -28.02%
Return on equity TTM -385.65%
Profit margin 0%
Book value N/A
Market capitalisation $3.5 billion

TTM: trailing 12 months

Shorting Legend Biotech Corporation shares

There are currently 2.2 million Legend Biotech Corporation shares held short by investors – that's known as Legend Biotech Corporation's "short interest". This figure is 40.8% down from 3.8 million last month.

There are a few different ways that this level of interest in shorting Legend Biotech Corporation shares can be evaluated.

Legend Biotech Corporation's "short interest ratio" (SIR)

Legend Biotech Corporation's "short interest ratio" (SIR) is the quantity of Legend Biotech Corporation shares currently shorted divided by the average quantity of Legend Biotech Corporation shares traded daily (recently around 380035.30405405). Legend Biotech Corporation's SIR currently stands at 5.92. In other words for every 100,000 Legend Biotech Corporation shares traded daily on the market, roughly 5920 shares are currently held short.

However Legend Biotech Corporation's short interest can also be evaluated against the total number of Legend Biotech Corporation shares, or, against the total number of tradable Legend Biotech Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Legend Biotech Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Legend Biotech Corporation shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Legend Biotech Corporation shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Legend Biotech Corporation.

Find out more about how you can short Legend Biotech Corporation stock.

Legend Biotech Corporation share dividends

We're not expecting Legend Biotech Corporation to pay a dividend over the next 12 months.

Legend Biotech Corporation overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site